Capri Holdings Ltd vs Zoetis Inc — how do they compare? Capri Holdings Ltd trades at $14.75 (market cap $1.67B), while Zoetis Inc trades at $74.33 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 18.1× Capri Holdings Ltd's market cap, and Zoetis Inc pays a 2.9% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Zoetis Inc for 70 Days on average.
| CPRI | ZTS | |
|---|---|---|
Market Cap | $1.67B | $30.20B |
Volume | 3,722,279 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $147.53 |
52-Week Low | $12.71 | $69.09 |
Typical Hold Time | 41 Days | 70 Days |
Enterprise Value | $2.95B | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.44, down 1.57% today, with a bearish technical outlook despite recent earnings beats. The stock shows mixed signals with strong profitability metrics (62.71% gross margin, 252.89% ROE) but concerning fundamental trends including declining revenue from $5.7B in 2022 to $4.4B in 2025 and a significant net loss of -$1.18B. Recent news highlights management's focus on brand revitalization and second-half growth expectations for Michael Kors and Jimmy Choo brands.
The investment case balances attractive valuation (P/S 0.51) against substantial operational challenges. Analyst consensus leans neutral with a $20.57 price target representing 42% upside, but investors face risks from continued revenue declines, high debt levels, and the ongoing Michael Kors turnaround execution. The stock offers potential value if management's growth initiatives gain traction in the second half of 2026.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Trailing returns across standard periods
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →